Pharmacogenomics and Obesity Treatment examines the genetic determinants of responses to weight management therapies. It covers genetic markers that predict efficacy and safety of pharmacological treatments for obesity. The book emphasizes personalized approaches to optimize weight loss strategies and reduce side effects. Targeted at endocrinologists and obesity specialists, it advances tailored treatments for effective obesity management.
Joshua Reid applies pharmacogenomics to obesity treatment within dermatology, focusing on managing skin conditions related to obesity such as acanthosis nigricans. His research explores how genetic variations influence responses to weight management medications and their impact on skin health. Joshua has published extensively on personalizing obesity pharmacotherapy to enhance dermatological outcomes through pharmacogenomic testing. He also provides guidelines for clinicians to incorporate pharmacogenomic insights into obesity treatment plans, promoting personalized and effective management of obesity-related skin conditions through genetic-informed strategies.